Athersys Inc.
| NASDAQ: ATHX | Healthcare / Biotechnology / USA |
| 1.40 | +0.2200 | +18.64% | Vol 617.07K | 1Y Perf -93.28% |
| Mar 22nd, 2023 14:00 DELAYED |
| BID | 1.40 | ASK | 1.41 | ||
| Open | 1.25 | Previous Close | 1.18 | ||
| Pre-Market | 1.25 | After-Market | - | ||
| 0.07 5.93% | - - |
| Target Price | 0.40 | Analyst Rating | Moderate Sell 4.00 | |
| Potential % | -71.83 | Finscreener Ranking | ☆ 25.00 | |
| Insiders Trans % 3/6/12 mo. | -/100/20 | Value Ranking | ☆ 19.77 | |
| Insiders Value % 3/6/12 mo. | -/100/41 | Growth Ranking | ☆ 6.52 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/59 | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.74 | Earnings Rating | Strong Sell | |
| Market Cap | 24.09M | Earnings Date | 21st Mar 2023 | |
| Alpha | 0.00 | Standard Deviation | 0.25 | |
| Beta | -1.30 |
Today's Price Range 1.251.51 | 52W Range 0.503133.25 | 5 Year PE Ratio Range -161.10-180.40 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -16.90% | ||
| 1 Month | -24.36% | ||
| 3 Months | 44.79% | ||
| 6 Months | 0.85% | ||
| 1 Year | -93.28% | ||
| 3 Years | -97.35% | ||
| 5 Years | -97.57% | ||
| 10 Years | -96.89% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -155.89 | |||
ROE last 12 Months | -1 970.03 | |||
ROA (5Y Avg) | -71.74 | |||
ROA last 12 Months | -168.19 | |||
ROC (5Y Avg) | -149.81 | |||
ROC last 12 Months | -519.68 | |||
Return on invested Capital Q | -123.56 | |||
Return on invested Capital Y | -66.74 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.20 | ||||
| 219.57 | ||||
| 3.54 | ||||
| - | ||||
| -0.30 | ||||
| -0.29 | ||||
| -0.99 | ||||
| -0.97 | ||||
| 11.69M | ||||
| Forward PE | -0.17 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.40 | ||||
| 0.50 | ||||
| 0.97 | ||||
| 31.01 | ||||
| - | ||||
| Leverage Ratio | -4.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -1 413.30 | ||||
| -1 384.70 | ||||
| -2 110.40 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.29M | ||||
| 0.31 | ||||
| -30.02 | ||||
| 2.51 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -1.96 | -1.15 | 41.33 |
| Q02 2022 | -1.75 | -2.25 | -28.57 |
| Q01 2022 | - | -2.25 | - |
| Q04 2021 | -1.75 | -2.25 | -28.57 |
| Q03 2021 | -2.00 | -1.75 | 12.50 |
| Q02 2021 | -2.00 | -2.50 | -25.00 |
| Q01 2021 | -0.08 | -0.13 | -62.50 |
| Q04 2020 | -0.09 | -0.11 | -22.22 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2022 QR | -0.03 | -101.46 | Negative |
| 12/2022 QR | -1.38 | 83.45 | Positive |
| 12/2022 FY | -6.92 | 20.82 | Positive |
| 12/2023 FY | -7.32 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 617.07K |
| Shares Outstanding | 17.21K |
| Shares Float | 246.85M |
| Trades Count | 1.96K |
| Dollar Volume | 875.82K |
| Avg. Volume | 166.85K |
| Avg. Weekly Volume | 110.63K |
| Avg. Monthly Volume | 114.50K |
| Avg. Quarterly Volume | 275.41K |
Athersys Inc. (NASDAQ: ATHX) stock closed at 1.18 per share at the end of the most recent trading day (a 0.85% change compared to the prior day closing price) with a volume of 74.56K shares and market capitalization of 24.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 104 people. Athersys Inc. CEO is Daniel A. Camardo.
The one-year performance of Athersys Inc. stock is -93.28%, while year-to-date (YTD) performance is 40.48%. ATHX stock has a five-year performance of -97.57%. Its 52-week range is between 0.5031 and 33.25, which gives ATHX stock a 52-week price range ratio of 2.74%
Athersys Inc. currently has a PE ratio of 0.20, a price-to-book (PB) ratio of 219.57, a price-to-sale (PS) ratio of 3.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -168.19%, a ROC of -519.68% and a ROE of -1 970.03%. The company’s profit margin is -%, its EBITDA margin is -1 384.70%, and its revenue ttm is $5.29 Million , which makes it $0.31 revenue per share.
Of the last four earnings reports from Athersys Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Athersys Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Athersys Inc. is Moderate Sell (4), with a target price of $0.4, which is -71.83% compared to the current price. The earnings rating for Athersys Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Athersys Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Athersys Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.88, ATR14 : 0.13, CCI20 : -232.22, Chaikin Money Flow : -0.18, MACD : -0.06, Money Flow Index : 41.09, ROC : -22.88, RSI : 34.24, STOCH (14,3) : 2.13, STOCH RSI : 0.05, UO : 30.35, Williams %R : -97.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Athersys Inc. in the last 12-months were: Daniel A. Camardo (Buy at a value of $54 960)
Athersys Inc.
Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
CEO: Daniel A. Camardo
Telephone: +1 216 431-9900
Address: 3201 Carnegie Avenue, Cleveland 44115-2634, OH, US
Number of employees: 104
